Trial Profile
Clinical and basic research of CD22-CAR T cells in the treatment of hematologic malignancy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2018
Price :
$35
*
At a glance
- Drugs Anti-CD22-chimeric-antigen-receptor-T-cell-therapy-Shanghai-Yake-Biotechnology (Primary)
- Indications Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai YaKe Biotechnology
- 02 Aug 2018 New trial record